Clinical Trial

Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment

Completed
View on ClinicalTrials.gov →
Summary
Hepatic arterial infuison chemothearpy (HAIC), targeted therapy, and programmed death-1 (PD-1) inhibitors have been demonstrated to be effective for colorectal cancer liver metastasis (CRCLM). Thus, the investigators will conduct a prospective trial to explore the efficacy and safety of targeted treatment based on genotyping or ctDNA genotyping combined with tislelizumab and HAIC as salvage treatment for advanced CRCLM failed from standard systemic treatment, aiming to provide individualized optimized regimen for microsatellite stable (MSS) CRCLM in salvage treatment.
Protocol Amendment History 4 changes
critical Trial completed 2026-07-29
minor Completion moved earlier: 2027-06-23 -> 2026-07-10 2026-07-29
notable Primary completion pushed: 2026-05-23 -> 2026-06-23 2026-06-10
minor Completion pushed: 2027-05-23 -> 2027-06-23 2026-06-10
Trial Details
NCT Number NCT06199232
Lead Sponsor Peking University
Conditions Liver Metastasis Colon Cancer, ctDNA Genotype, MSS, Failed From Standard Treatment
Enrollment 47 participants
Start Date 2024-01-23
Primary Completion 2026-07-10 (estimated)
Study Completion 2026-07-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-28